PHILADELPHIA – Results of a new study call into question recent clinical guidelines issued by leading cardiovascular groups, including the American Heart Association, which recommend patients with cardiovascular disease be screened for signs of depression and treated accordingly. The study, published in the November 12 edition of the Journal of the American Medical Association and conducted by an international team of researchers including James Coyne, Ph.D., Professor of Psychology in Psychiatry at the Perelman School of Medicine, determined that there is no clear evidence that depression screening plays a conclusive role in improving cardiovascular patients' health.
Nearly one in five patients with cardiovascular disease suffer from major depressive disorder, but because some heart disease symptoms can be confused with signs of depression, standard screening tools for depression may not be appropriate for this patient population.
“If a patient has a positive score on a depression screening test, most cardiologists do not have the time or training to conduct a follow-up interview, rule out false-positive results and establish an appropriate depression treatment plan.” said Dr. Coyne. “Given the scientific evidence concerning the necessary steps to diagnose and treat depression effectively, cardiologists should be discouraged from dispensing antidepressants casually, without proper diagnosis and follow up planning.”
Even if treatment improves depression, investigators found no evidence that improvement in depression results in delaying a new heart attack or improving survival, but noted that the relevant data were quite limited.
“For a patient to benefit from depression treatment, they need to receive comprehensive education, an appropriate treatment (i.e. medication, psychotherapy) and a follow-up care to monitor progress,” Coyne said. “That is hard to accomplish in a busy cardiology practice and may not benefit the cardiac health of the patient.”
In addition to Dr. Coyne, other researchers who contributed to this study were Brett Thombs, Ph.D. of McGill University and the affiliated Jewish General Hospital, Roy Ziegelstein, M.D., Johns Hopkins University School of Medicine, Peter de Jonge, Ph.D., at the University Medical Center Groningen, Netherlands; Mary Whooley, M.D., at the University of California, San Francisco; Nancy Frasure-Smith, Ph.D., also at McGill; Alex Mitchell, M.Sc., M.R.C. Psych, at the Leicester Royal Infirmary, United Kingdom; Marij Zuidersma, M.Sc., also at Groningen; Cheri Smith, M.L.S., and Karl Soderlund, B.S., at Johns Hopkins, Chete Eze-Nliam, M.D., M.P.H., at Interfaith Medical Center in Brooklyn, N.Y.; and Bruno Lima, at Federal University of Ceara School of Medicine, in Fontalez-ce, Brazil.
PENN Medicine is a $3.6 billion enterprise dedicated to the related missions of medical education, biomedical research, and excellence in patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System.
Penn's School of Medicine is currently ranked #4 in the nation in U.S.News & World Report's survey of top research-oriented medical schools; and, according to most recent data from the National Institutes of Health, received over $379 million in NIH research funds in the 2006 fiscal year. Supporting 1,700 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.
The University of Pennsylvania Health System (UPHS) includes its flagship hospital, the Hospital of the University of Pennsylvania, rated one of the nation’s top ten “Honor Roll” hospitals by U.S.News & World Report; Pennsylvania Hospital, the nation's first hospital; and Penn Presbyterian Medical Center. In addition UPHS includes a primary-care provider network; a faculty practice plan; home care, hospice, and nursing home; three multispecialty satellite facilities; as well as the Penn Medicine Rittenhouse campus, which offers comprehensive inpatient rehabilitation facilities and outpatient services in multiple specialties.
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $5.3 billion enterprise.
The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 18 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $373 million awarded in the 2015 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.